Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc.

Clostridium difficile infection (CDI)

500K US cases/yr

Disease Overview

C. difficile infection (CDI) is a toxin-mediated colitis triggered by broad-spectrum antibiotic disruption of normal gut flora, producing severe diarrhea, pseudomembranous colitis, and risk of sepsis. The CDC declared CDI an 'urgent threat,' with elderly hospitalized patients carrying the highest mortality and ~25% of treated patients suffering recurrence on standard vancomycin/metronidazole.

Competitive Landscape

At deal signing in March 2012, the global CDI armamentarium consisted of generic oral vancomycin (Vancocin and ANDAs), oral metronidazole (Flagyl, generic), and the newly approved Dificid (fidaxomicin, US FDA approval May 2011; EU approval as Dificlir Dec 2011). Fidaxomicin was differentiated by a non-inferior cure rate plus a roughly 50% reduction in 28-day recurrence versus vancomycin in the OPT-80-003/004 pivotal trials, validating the macrocyclic narrow-spectrum approach. Pipeline competitors at the time included Merck/Medarex actoxumab + bezlotoxumab (anti-toxin mAbs, later Zinplava 2016), Sanofi's Cdiffense vaccine candidate, and various fecal microbiota approaches. The Astellas deal mattered because Optimer lacked Japan infrastructure and Astellas owned strong Japanese hospital and ID prescriber relationships; the structure (modest $20M upfront + $70M milestones + double-digit royalty) preserved most economic upside for Optimer while de-risking Japan PMDA development.